Portland, OR -- (SBWIRE) -- 10/03/2017 -- Etanercept are biopharmaceutical anti-Tumor Necrosis Factor (TNF) that treats autoimmune diseases such as arthritis and spondylitis. Over production of TNF in the body causes inflammation, pain, and damage to the bones and joints. Etanercept blocks the action of TNF and reduces the inflammation. It is prescribed to treat juvenile rheumatoid arthritis, rheumatoid arthritis, and psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.
Increase in prevalence of arthritis and spondylitis owing to the rise in incidences of obesity and accidents majorly drive the etanercept market. Furthermore, the increase in healthcare expenditure and awareness of arthritis by government private organizations is anticipated to increase the market growth. However, stringent government regulations associated with the safety and efficacy of etanercept hinder the market growth.
In addition, side effects of etanercept such as lowering ability of immune system, heart failure, seizers, blood problems, and others is anticipated to hinder the market growth. Ongoing R&D activities related to etanercept are anticipated to present new opportunities for the market.
Get the PDF brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/4204
The market is segmented on the basis of application and region. Based on application, it is categorized into Arthritis, Psoriasis, and Spondylitis. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Etanercept Market Key Segments:
List of players profiled in the report
-Takeda Pharmaceutical Company Ltd
-Johnson & Johnson
-GlaxoSmithKline Pharmaceuticals Ltd
-Samsung Bioepis Co., Ltd.
-F.Hoffmann-La Roche Ltd
-Novartis International AG
Get 20% discount on this report